This HTML5 document contains 181 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01112/identifier/chebi/
n7http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/mesh/concept/
n10http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01112/identifier/wikipedia/
n27http://linked.opendata.cz/resource/drugbank/drug/DB01112/identifier/pharmgkb/
n30http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB01112/identifier/kegg-compound/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01112/identifier/pdb/
admshttp://www.w3.org/ns/adms#
n18http://www.rxlist.com/cgi/generic/
n29http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/drug/DB01112/identifier/kegg-drug/
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01112/identifier/drugbank/
n4http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n12http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01112/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01112
rdf:type
n4:Drug
n4:description
Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. [PubChem]
n4:dosage
n15:271B41C9-363D-11E5-9242-09173F13E4C5 n15:271B41CA-363D-11E5-9242-09173F13E4C5 n15:271B41CB-363D-11E5-9242-09173F13E4C5 n15:271B41CC-363D-11E5-9242-09173F13E4C5 n15:271B41C8-363D-11E5-9242-09173F13E4C5 n15:271B41D1-363D-11E5-9242-09173F13E4C5 n15:271B41D2-363D-11E5-9242-09173F13E4C5 n15:271B41D3-363D-11E5-9242-09173F13E4C5 n15:271B41D4-363D-11E5-9242-09173F13E4C5 n15:271B41CD-363D-11E5-9242-09173F13E4C5 n15:271B41CE-363D-11E5-9242-09173F13E4C5 n15:271B41CF-363D-11E5-9242-09173F13E4C5 n15:271B41D0-363D-11E5-9242-09173F13E4C5 n15:271B41D5-363D-11E5-9242-09173F13E4C5 n15:271B41D6-363D-11E5-9242-09173F13E4C5 n15:271B41D7-363D-11E5-9242-09173F13E4C5 n15:271B41D8-363D-11E5-9242-09173F13E4C5
n4:generalReferences
# Perry CM, Brogden RN: Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1996 Jul;52(1):125-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8799689
n4:group
approved
n4:halfLife
Approximately 80 minutes following intramuscular or intravenous injection.
n4:indication
For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
owl:sameAs
n17:DB01112 n30:DB01112
dcterms:title
Cefuroxime
adms:identifier
n14:Cefuroxime n21:DB01112 n22:3515 n23:0469-7220-01 n24:CES n25:C06894 n26:D00262 n27:PA448868
n4:mechanismOfAction
Cefuroxime, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefuroxime interferes with an autolysin inhibitor.
n4:packager
n10:271B4193-363D-11E5-9242-09173F13E4C5 n10:271B4191-363D-11E5-9242-09173F13E4C5 n10:271B4192-363D-11E5-9242-09173F13E4C5 n10:271B418F-363D-11E5-9242-09173F13E4C5 n10:271B4190-363D-11E5-9242-09173F13E4C5 n10:271B418D-363D-11E5-9242-09173F13E4C5 n10:271B418E-363D-11E5-9242-09173F13E4C5 n10:271B418B-363D-11E5-9242-09173F13E4C5 n10:271B418C-363D-11E5-9242-09173F13E4C5 n10:271B4189-363D-11E5-9242-09173F13E4C5 n10:271B418A-363D-11E5-9242-09173F13E4C5 n10:271B4187-363D-11E5-9242-09173F13E4C5 n10:271B4188-363D-11E5-9242-09173F13E4C5 n10:271B41A1-363D-11E5-9242-09173F13E4C5 n10:271B41A2-363D-11E5-9242-09173F13E4C5 n10:271B419F-363D-11E5-9242-09173F13E4C5 n10:271B41A0-363D-11E5-9242-09173F13E4C5 n10:271B419D-363D-11E5-9242-09173F13E4C5 n10:271B419E-363D-11E5-9242-09173F13E4C5 n10:271B419B-363D-11E5-9242-09173F13E4C5 n10:271B419C-363D-11E5-9242-09173F13E4C5 n10:271B4199-363D-11E5-9242-09173F13E4C5 n10:271B419A-363D-11E5-9242-09173F13E4C5 n10:271B4186-363D-11E5-9242-09173F13E4C5 n10:271B4198-363D-11E5-9242-09173F13E4C5 n10:271B4184-363D-11E5-9242-09173F13E4C5 n10:271B4185-363D-11E5-9242-09173F13E4C5 n10:271B4182-363D-11E5-9242-09173F13E4C5 n10:271B4183-363D-11E5-9242-09173F13E4C5 n10:271B4180-363D-11E5-9242-09173F13E4C5 n10:271B4181-363D-11E5-9242-09173F13E4C5 n10:271B4197-363D-11E5-9242-09173F13E4C5 n10:271B417E-363D-11E5-9242-09173F13E4C5 n10:271B417F-363D-11E5-9242-09173F13E4C5 n10:271B4176-363D-11E5-9242-09173F13E4C5 n10:271B4195-363D-11E5-9242-09173F13E4C5 n10:271B4177-363D-11E5-9242-09173F13E4C5 n10:271B4196-363D-11E5-9242-09173F13E4C5 n10:271B4174-363D-11E5-9242-09173F13E4C5 n10:271B417D-363D-11E5-9242-09173F13E4C5 n10:271B4175-363D-11E5-9242-09173F13E4C5 n10:271B4194-363D-11E5-9242-09173F13E4C5 n10:271B417B-363D-11E5-9242-09173F13E4C5 n10:271B4172-363D-11E5-9242-09173F13E4C5 n10:271B417C-363D-11E5-9242-09173F13E4C5 n10:271B4173-363D-11E5-9242-09173F13E4C5 n10:271B4179-363D-11E5-9242-09173F13E4C5 n10:271B4170-363D-11E5-9242-09173F13E4C5 n10:271B417A-363D-11E5-9242-09173F13E4C5 n10:271B4171-363D-11E5-9242-09173F13E4C5 n10:271B416E-363D-11E5-9242-09173F13E4C5 n10:271B4178-363D-11E5-9242-09173F13E4C5 n10:271B416F-363D-11E5-9242-09173F13E4C5 n10:271B416C-363D-11E5-9242-09173F13E4C5 n10:271B416D-363D-11E5-9242-09173F13E4C5
n4:patent
n29:1328405 n29:2408198
n4:synonym
Cefuroximo Cefuroxim Cefuroxime Cephuroxime Cefuroximum Sharox (6R,7R)-3-[(Carbamoyloxy)methyl]-7-{[(2Z)-2-furan-2-yl-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Zinacef danmark
n4:toxicity
Allergic reactions might be expected, including rash, nasal congestion, cough, dry throat, eye irritation, or anaphylactic shock. Overdosage of cephalosporins can cause cerebral irritation leading to convulsions.
n6:hasAHFSCode
n7:08-12-06-08
n4:foodInteraction
Take with food to increase absorption.
n4:proteinBinding
50% to serum protein
n4:synthesisReference
Vijay Kumar Handa, Ramesh Dandala, Jag Mohan Khanna, "Process for the preparation of cefuroxime." U.S. Patent US6235896, issued February, 1976.
n19:hasConcept
n20:M0003733
foaf:page
n12:cef1076.shtml n18:cefurox.htm n28:cefuroxime.html
n4:IUPAC-Name
n5:271B41DD-363D-11E5-9242-09173F13E4C5
n4:InChI
n5:271B41E3-363D-11E5-9242-09173F13E4C5
n4:Molecular-Formula
n5:271B41E2-363D-11E5-9242-09173F13E4C5
n4:Molecular-Weight
n5:271B41DF-363D-11E5-9242-09173F13E4C5
n4:Monoisotopic-Weight
n5:271B41E0-363D-11E5-9242-09173F13E4C5
n4:SMILES
n5:271B41E1-363D-11E5-9242-09173F13E4C5
n4:Water-Solubility
n5:271B41DB-363D-11E5-9242-09173F13E4C5 n5:271B41F3-363D-11E5-9242-09173F13E4C5
n4:logP
n5:271B41DC-363D-11E5-9242-09173F13E4C5 n5:271B41D9-363D-11E5-9242-09173F13E4C5 n5:271B41F5-363D-11E5-9242-09173F13E4C5
n4:logS
n5:271B41DA-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n9:J01DC02 n9:S01AA27
n4:H-Bond-Acceptor-Count
n5:271B41E9-363D-11E5-9242-09173F13E4C5
n4:H-Bond-Donor-Count
n5:271B41EA-363D-11E5-9242-09173F13E4C5
n4:InChIKey
n5:271B41E4-363D-11E5-9242-09173F13E4C5
n4:Polar-Surface-Area--PSA-
n5:271B41E5-363D-11E5-9242-09173F13E4C5
n4:Polarizability
n5:271B41E7-363D-11E5-9242-09173F13E4C5
n4:Refractivity
n5:271B41E6-363D-11E5-9242-09173F13E4C5
n4:Rotatable-Bond-Count
n5:271B41E8-363D-11E5-9242-09173F13E4C5
n4:absorption
Absorbed from the gastrointestinal tract. Absorption is greater when taken after food (absolute bioavailability increases from 37% to 52%).
n4:affectedOrganism
Enteric bacteria and other eubacteria
n4:casRegistryNumber
55268-75-2
n4:category
n4:containedIn
n8:271B41C2-363D-11E5-9242-09173F13E4C5 n8:271B41AD-363D-11E5-9242-09173F13E4C5 n8:271B41C1-363D-11E5-9242-09173F13E4C5 n8:271B41AB-363D-11E5-9242-09173F13E4C5 n8:271B41AC-363D-11E5-9242-09173F13E4C5 n8:271B41AA-363D-11E5-9242-09173F13E4C5 n8:271B41C6-363D-11E5-9242-09173F13E4C5 n8:271B41C7-363D-11E5-9242-09173F13E4C5 n8:271B41C4-363D-11E5-9242-09173F13E4C5 n8:271B41C5-363D-11E5-9242-09173F13E4C5 n8:271B41C0-363D-11E5-9242-09173F13E4C5 n8:271B41C3-363D-11E5-9242-09173F13E4C5 n8:271B41BE-363D-11E5-9242-09173F13E4C5 n8:271B41BF-363D-11E5-9242-09173F13E4C5 n8:271B41BC-363D-11E5-9242-09173F13E4C5 n8:271B41BD-363D-11E5-9242-09173F13E4C5 n8:271B41BA-363D-11E5-9242-09173F13E4C5 n8:271B41BB-363D-11E5-9242-09173F13E4C5 n8:271B41B7-363D-11E5-9242-09173F13E4C5 n8:271B41B8-363D-11E5-9242-09173F13E4C5 n8:271B41B3-363D-11E5-9242-09173F13E4C5 n8:271B41B4-363D-11E5-9242-09173F13E4C5 n8:271B41B1-363D-11E5-9242-09173F13E4C5 n8:271B41B2-363D-11E5-9242-09173F13E4C5 n8:271B41AF-363D-11E5-9242-09173F13E4C5 n8:271B41B0-363D-11E5-9242-09173F13E4C5 n8:271B41A9-363D-11E5-9242-09173F13E4C5 n8:271B41AE-363D-11E5-9242-09173F13E4C5 n8:271B41A7-363D-11E5-9242-09173F13E4C5 n8:271B41A8-363D-11E5-9242-09173F13E4C5 n8:271B41A5-363D-11E5-9242-09173F13E4C5 n8:271B41A6-363D-11E5-9242-09173F13E4C5 n8:271B41A3-363D-11E5-9242-09173F13E4C5 n8:271B41A4-363D-11E5-9242-09173F13E4C5 n8:271B41B5-363D-11E5-9242-09173F13E4C5 n8:271B41B9-363D-11E5-9242-09173F13E4C5 n8:271B41B6-363D-11E5-9242-09173F13E4C5
n4:Bioavailability
n5:271B41EF-363D-11E5-9242-09173F13E4C5
n4:Ghose-Filter
n5:271B41F1-363D-11E5-9242-09173F13E4C5
n4:MDDR-Like-Rule
n5:271B41F2-363D-11E5-9242-09173F13E4C5
n4:Melting-Point
n5:271B41F4-363D-11E5-9242-09173F13E4C5
n4:Number-of-Rings
n5:271B41EE-363D-11E5-9242-09173F13E4C5
n4:Physiological-Charge
n5:271B41ED-363D-11E5-9242-09173F13E4C5
n4:Rule-of-Five
n5:271B41F0-363D-11E5-9242-09173F13E4C5
n4:Traditional-IUPAC-Name
n5:271B41DE-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-acidic-
n5:271B41EB-363D-11E5-9242-09173F13E4C5
n4:pKa--strongest-basic-
n5:271B41EC-363D-11E5-9242-09173F13E4C5